Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity
Author:
Affiliation:
1. Receptos Inc; San Diego CA USA
2. Department of Chemical Physiology; The Scripps Research Institute; La Jolla CA USA
3. Department of Chemistry; The Scripps Research Institute; La Jolla CA USA
Publisher
Wiley
Subject
Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bph.13476/fullpdf
Reference61 articles.
1. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors;Alexander;Br J Pharmacol,2015a
2. The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors;Alexander;Br J Pharmacol,2015b
3. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes;Alexander;Br J Pharmacol,2015c
4. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation;Allende;Blood,2003
5. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis;Balatoni;Brain Res Bull,2007
Cited by 234 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis;Expert Opinion on Drug Metabolism & Toxicology;2024-09-12
2. Cardiac Safety of Ozanimod Use, a Novel Sphingosine-1-Phosphate Receptor Ligand, in COVID-19 Patients Requiring Oxygen: Secondary Analysis of the COZI Randomized Clinical Trial;CJC Open;2024-09
3. Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons;Journal of Comparative Effectiveness Research;2024-08-19
4. Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models;American Journal of Physiology-Gastrointestinal and Liver Physiology;2024-08-01
5. Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis;Inflammatory Bowel Diseases;2024-07-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3